Trials / Completed
CompletedNCT01137604
A Study in Subjects With Recurrent Malignant Glioma
An Open-Label, Three-Cohort, Phase 2 Study of E7080 (Lenvatinib) in Subjects With Recurrent Malignant Glioma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
An open-label phase 2, multicenter study in participants with recurrent malignant glioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | 24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent. |
| DRUG | Bevacizumab | Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent. |
Timeline
- Start date
- 2010-11-09
- Primary completion
- 2013-03-19
- Completion
- 2014-10-28
- First posted
- 2010-06-04
- Last updated
- 2022-09-29
- Results posted
- 2016-05-23
Locations
5 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01137604. Inclusion in this directory is not an endorsement.